Cargando…

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Karalis, Vangelis, Ntanasis-Stathopoulos, Ioannis, Apostolakou, Filia, Gumeni, Sentiljana, Gavriatopoulou, Maria, Papadopoulos, Dimitris, Malandrakis, Panagiotis, Papanagnou, Eleni-Dimitra, Korompoki, Eleni, Kastritis, Efstathios, Papassotiriou, Ioannis, Trougakos, Ioannis P., Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687721/
https://www.ncbi.nlm.nih.gov/pubmed/34938959
http://dx.doi.org/10.1097/HS9.0000000000000677
_version_ 1784618231038738432
author Terpos, Evangelos
Karalis, Vangelis
Ntanasis-Stathopoulos, Ioannis
Apostolakou, Filia
Gumeni, Sentiljana
Gavriatopoulou, Maria
Papadopoulos, Dimitris
Malandrakis, Panagiotis
Papanagnou, Eleni-Dimitra
Korompoki, Eleni
Kastritis, Efstathios
Papassotiriou, Ioannis
Trougakos, Ioannis P.
Dimopoulos, Meletios A.
author_facet Terpos, Evangelos
Karalis, Vangelis
Ntanasis-Stathopoulos, Ioannis
Apostolakou, Filia
Gumeni, Sentiljana
Gavriatopoulou, Maria
Papadopoulos, Dimitris
Malandrakis, Panagiotis
Papanagnou, Eleni-Dimitra
Korompoki, Eleni
Kastritis, Efstathios
Papassotiriou, Ioannis
Trougakos, Ioannis P.
Dimopoulos, Meletios A.
author_sort Terpos, Evangelos
collection PubMed
description The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study was to prospectively evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months in healthy individuals (NCT04743388). The assessments were performed at the following time points after the second vaccination: 2 weeks, 1 month, 3 months, 6 months, and 9 months. The measurements were performed with the GenScript’s cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ) and the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH; Mannheim, Germany). Three hundred nine participants with a median age of 48 years were included. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. Both NAbs and anti-S-RBD IgGs levels were significantly lower at 9 months compared with the previous timepoints. Interestingly, age was found to exert a statistically significant effect on NAbs elimination only during the first-trimester postvaccination, as older age was associated with a more rapid clearance of NAbs. Furthermore, simulation studies predicted that the median NAb value would fall from 66% at 9 months to 59% and 45% at 12 and 18 months postvaccination, respectively. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks.
format Online
Article
Text
id pubmed-8687721
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-86877212021-12-21 Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals Terpos, Evangelos Karalis, Vangelis Ntanasis-Stathopoulos, Ioannis Apostolakou, Filia Gumeni, Sentiljana Gavriatopoulou, Maria Papadopoulos, Dimitris Malandrakis, Panagiotis Papanagnou, Eleni-Dimitra Korompoki, Eleni Kastritis, Efstathios Papassotiriou, Ioannis Trougakos, Ioannis P. Dimopoulos, Meletios A. Hemasphere Article The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study was to prospectively evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months in healthy individuals (NCT04743388). The assessments were performed at the following time points after the second vaccination: 2 weeks, 1 month, 3 months, 6 months, and 9 months. The measurements were performed with the GenScript’s cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ) and the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH; Mannheim, Germany). Three hundred nine participants with a median age of 48 years were included. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. Both NAbs and anti-S-RBD IgGs levels were significantly lower at 9 months compared with the previous timepoints. Interestingly, age was found to exert a statistically significant effect on NAbs elimination only during the first-trimester postvaccination, as older age was associated with a more rapid clearance of NAbs. Furthermore, simulation studies predicted that the median NAb value would fall from 66% at 9 months to 59% and 45% at 12 and 18 months postvaccination, respectively. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks. Lippincott Williams & Wilkins 2021-12-17 /pmc/articles/PMC8687721/ /pubmed/34938959 http://dx.doi.org/10.1097/HS9.0000000000000677 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Terpos, Evangelos
Karalis, Vangelis
Ntanasis-Stathopoulos, Ioannis
Apostolakou, Filia
Gumeni, Sentiljana
Gavriatopoulou, Maria
Papadopoulos, Dimitris
Malandrakis, Panagiotis
Papanagnou, Eleni-Dimitra
Korompoki, Eleni
Kastritis, Efstathios
Papassotiriou, Ioannis
Trougakos, Ioannis P.
Dimopoulos, Meletios A.
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
title Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
title_full Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
title_fullStr Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
title_full_unstemmed Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
title_short Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
title_sort sustained but declining humoral immunity against sars-cov-2 at 9 months postvaccination with bnt162b2: a prospective evaluation in 309 healthy individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687721/
https://www.ncbi.nlm.nih.gov/pubmed/34938959
http://dx.doi.org/10.1097/HS9.0000000000000677
work_keys_str_mv AT terposevangelos sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT karalisvangelis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT ntanasisstathopoulosioannis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT apostolakoufilia sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT gumenisentiljana sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT gavriatopouloumaria sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT papadopoulosdimitris sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT malandrakispanagiotis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT papanagnouelenidimitra sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT korompokieleni sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT kastritisefstathios sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT papassotiriouioannis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT trougakosioannisp sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals
AT dimopoulosmeletiosa sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals